ArticleOral oncology2016

Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Loren Michel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.